TO THE EDITOR
Even though the prognostic value of cytomorphological, immunologic, cytogenetic and molecular markers at diagnosis of childhood ALL is widely assessed, the meaning of possible marker shifts from diagnosis to relapse, possibly helpful in clarifying the nature of the leukemic relapse, is not well known, mainly because of heterogeneity in monoclonal antibody panels and difficulty in finding sufficient mononuclear cells stored. [1] [2] [3] [4] Immunophenotype shifts, reported in about half of relapses in at least one antigen, seem due to the proliferation of drug resistant cells, belonging to the original leukemic clone, which could develop loss or acquisition of membrane antigens or even have multilineage properties; nevertheless the emergence of a novel independent clone as a secondary malignancy cannot be ruled out. 2 Major immunophenotype changes leading to switches from lymphoid to myeloid lineage or vice versa, are defined as inter-lineage shifts; minor ones determined by losses or acquisitions of one or more antigens, leading to switches in the immunophenotypic classification within B lineage ALL (pre-pre B, common, pre-B, B mature) or within T-ALL (immature, intermediate, mature), are defined as intra-lineage shifts. 2 We report the case of a 14-year-old Italian girl, who, in March 1993, presented with pallor and low-grade fever, cervical lymph node enlargement and abnormal peripheral counts (hemoglobin: 8.4 g/dl, white blood cells: 20.6 × 10 9 /l, platelets: 22 × 10 9 /l); the morphology of peripheral blood (PB) and bone marrow (BM) smears revealed 74% and 98% of blasts respectively, and allowed the diagnosis of ALL, L2, according to the FAB classification. The expression of surface Ig (sIg), and chains and antigens CD10, CD19, CD5, CD3, CD7, HLA-DR, CD13, CD33, CD34, were assessed by direct immunofluorescence and analyzed by means of a FACScan flow cytometer. The TdT expression was tested by incubation with direct labelled monoclonal antibodies after fixation and permeabilization (Fix & Perm; Caltag, San Francisco, CA, USA). The expression of cytoplasmic IgM (cyIgM) was tested by immunofluorescence microscopy on cytospin preparations after fixation in 5% acetic ethanol acid. 5 HLA-DR, TdT and CD19 were positive in virtually all blasts, CD5 and CD34 and cyIgM in a relevant proportion of blasts, while sIg were virtually absent (Table 1, Figure 1a -c). The positivity of cyIgM allowed classification of this ALL as a pre-B. Cytogenetic analysis, performed as previously described, showed the following karyotype: 46,XX,del(9)(p21) [5] /46,XX,−3,+8, del(9)(p21) [7] /46,XX [4] . The girl was treated according to the 9102 protocol of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP), showed good steroid response, obtained complete remission after the induction phase and discontinued her uneventful 2-year course of chemotherapy in March 1995. Nineteen months after the discontinuation of chemotherapy, the girl presented with bone pain, lymph node enlargement and low counts and the BM aspirate revealed 99% of blasts with L3 morphology. The immunophenotype performed at relapse detected HLA-DR, CD19, CD5 and sIg positivity and TdT negativity in virtually all blasts (Table 1, Figure 1d-g ). The following karyotype was detected: 46,XX,del(9)(p21) [2] /46,XX,−3,+8, del(9)(p21) [4] /46,XX [5] . The AIEOP 8805, a BFM-like protocol designed as mature B ALL front-line treatment, was administered and well tolerated; a prompt remission was obtained and maintained by a 4-month course of chemotherapy, since no HLA-compatible donors were available. The girl relapsed 2 months after the second discontinuation of chemotherapy. The BM aspirate revealed unchanged morphology and immunophenotype compared with the first relapse except for the TdT positivity (Table 1) . Palliative therapy was administered and the girl died 2 months later. In order to investigate whether the recurrent disease was due to the same leukemic clone or to a second malignant clone, the clonality of DNA samples from diagnosis and relapse was investigated by PCR analysis of Ig light and IgH chain gene rearrangements. 6 PCRs of most common recombinations were performed for Ig (vkll-Kde and IRSS-Kde);
6 FR1c and JHc primers were used for IgH analysis. 7 PCR amplification was performed as previously described and 10 to 100 l of PCR products were run in non-denaturing polyacrylamide gel electrophoresis (PAGE). [5] [6] [7] The homoduplex band corresponding to the IRSS-Kde rearrangement was observed at relapse but not at diagnosis, while in the IgH analysis the same rearranged bands were obtained at diagnosis and relapse (data not shown). After the identification of IRSS-Kde and FR1c-JHc rearrangements, the sequences of both junctional regions were defined by direct sequence analysis (Direct Sequence Kit, Perkin Elmer, Norwalk, CT, USA). Based on the sequence data obtained, patient-specific oligonucleotides were developed and used in the dot blot experiment, as shown in Figure 2 . This is the first case, to our knowledge, of an intra-lineage shift from precursor-B ALL at diagnosis to mature-B ALL at relapse. Homogeneous patterns at diagnosis and relapse, ie cytogenetics, repeated unusual positivity for a T cell marker (CD5) and, most of all, concordant IgH rearrangement, as assessed by PCR amplification and sequence analysis, suggested that we were dealing with the recurrence of the same original clone rather than with a secondary malignancy.
The coexpression of CD19 with the T cell antigen CD5, extremely rare in ALL, was recently reported, in the absence of CD45 molecule and TdT, by Subirà et al. 8 It is worthwhile noting that this was the only CD5
+ case in our series of B-lineage ALL, among 310 children tested either at diagnosis (255) or at relapse (55). In this patient the detection of the CD5 antigen in a fraction of blasts at diagnosis and in virtually all blasts at relapse might support the hypothesis that the relapsed clone, already present at the onset of the disease, as a CD5 + subgroup, showed drug resistance, whereas the front-line chemotherapy lead to the eradication of the CD5 − population only. Nevertheless the maturation of a unique initial leukemic clone, in terms of acquisition of membrane antigens up to the mature B stage, seems more likely than the hypotheses of two possible clones at presentation,
Figure 1
Representative cytograms and histograms of flow cytometric analysis performed at diagnosis (a, b and c) and first relapse (d, e, f and g). Selection of blast cell population was assessed by placing an electronic gate according to the forward side scatter (FSC) and side scatter (SSC) profile at diagnosis (a) and relapse (d). Double staining with anti-CD19 FITC and anti-CD5 PE shows the co-expression of these antigens on blast cells at diagnosis (b) and relapse (e). Fluorescence histograms of surface immunoglobulin (sIg) expression at diagnosis and relapse are shown in c and f, respectively. Double staining with anti-FITC and anti-PE at relapse demonstrates monoclonality of surface immunoglobulin expression for light chains as shown in g.
Figure 2
IgH and Ig rearrangement analysis at diagnosis and relapses. Genomic DNA from diagnosis and relapses was subjected to PCR analysis using the FR1c-5Ј and JHc-3Ј IgH-specific primers and using the IRSS-5Ј and Kde-3Ј Ig-specific primers. Both IgH and Igspecific PCR products were spotted in duplicate on to the nylon membrane and hybridized with the patient-specific probe. Mononuclear cells (MNC) from a healthy volunteer donor served as a control. Dotblot results for IgH and Ig are shown in a and b, respectively. because the same IgH chain rearrangement was already present at the onset, while chain gene deletion was detectable at relapse only.
This case underlines the important role of comparative studies, mainly at the molecular level, between disease patterns at diagnosis and relapse, as potential means yielding valuable insights into the mechanism of leukemic recurrence.
Therapy-related T cell lymphoblastic lymphoma with t(11;19)(q23;p13) and MLL gene rearrangement

TO THE EDITOR
During the past several decades, advances in the treatment of childhood cancers have resulted in increased survival of pediatric cancer patients. This is in large part due to the use of aggressive chemotherapy regimens, radiation therapy or a combination of both. However, along with the benefits of increased survival. It has become 
apparent that survivors of childhood cancer are at increased risk of second malignancies. [1] [2] [3] [4] [5] [6] A number of factors have been implicated in the etiology of second malignancies. The original cancer and associated genetic factors, immunosuppression, radiation therapy, and chemotherapy have been proposed as potential etiologic factors. [1] [2] [3] [4] [5] [6] In some instances an interaction of two or more of these factors has been associated with the development of second cancers. [3] [4] [5] For example, patients with Hodgkin's disease show an increased incidence of several malignancies following combined chemotherapy and radiation therapy, and patients with hereditary retinoblastoma are prone to developing osteogenic sarcoma when treated with radiation therapy. 4 The increased risk of secondary hematological malignancies in patients exposed to alkylating agents 7 and epipodophyllotoxins 2,3 is
Figure 2
The MLL rearrangement was not constitutional. BamHI digested DNA extracted from the patient's peripheral blood lymphocytes (PBL) prior to the leukemic phase was hybridized to the 0.7B MLL probe. The MOLT 4 cell line is used as a germline control. Size standards are as indicated. A single germline fragment is seen in both the control and the patient PBL sample indicating that the MLL rearrangement seen in the tumor cells is not due to a restriction fragment length polymorphism. treatment with an alkylating agent and an epipodophyllotoxin. While it is possible that therapy-related lymphoblastic lymphoma has a longer latency period than therapy-related leukemia, wide variations in latency periods for secondary malignancies with the 11q23 translocation following similar treatment regimens have been reported. 2 What is the cause for the second malignancy in this patient? There was no history of a hereditary predisposition to malignancies in the family. To our knowledge there is no association between primary hepatocellular carcinoma and lymphoblastic lymphoma and the possibility that these were two unrelated de novo malignancies cannot be eliminated. However, the known association between 11q23 translocations and therapy-related acute leukemias make it likely that the lymphoblastic lymphoma in this patient was a direct result of an MLL translocation induced by treatment with DNA damaging agents. The mechanisms(s) of illegitimate recombination leading to MLL rearrangements is not well understood nor is the role of topo-II in this process. These topics have recently been reviewed. 3 We conclude that therapy-related lymphoblastic lymphoma can be associated with 11q23 translocations involving the MLL gene. While the case described here had a slightly longer latency period compared with the t-AMLs associated with the topo II poisons, it seems likely Extensive bone marrow necrosis associated with multiple myeloma TO that the mechanism of 11q23 translocation in this patient is similar to that seen in t-AMLs associated with topo II poisons. Although this entity is presumably rare, the true frequency with which therapyrelated lymphoblastic lymphoma occurs following aggressive, multiagent chemotherapy can only be ascertained by careful follow-up of cancer survivors.
extensive BMN is characterized by the development of fever, bone pain, a leukoerythroblastic peripheral blood film, variable degrees of pancytopenia and elevations of lactate dehydrogenase and alkaline phosphatase. BMN has been reported in patients with different malignancies, sickle cell disease, disseminated intravascular coagulation (DIC), antiphospholipid syndrome (APS), as well as infections. 1 There are case reports linking certain medications including fludarabine, interferon alfa to the development of BMN as well. 2, 3 Here we report two cases of multiple myeloma (MM) with extensive BMN.
In case 1, a 45-year-old man was diagnosed with Durie-Salmon stage III MM in June 1995. A serum immunoelectrophoresis and
